Harrington Discovery Institute requires that all applicants meet the following criteria:
- Hold an MD or MD/PhD from an accredited institution.
- Hold a faculty position at an accredited academic medical center, university or research institution in the US and conduct the majority of his/her research activities at that institution.
- A project may have only a single PI who will be responsible for project oversight and financial management. The PI may engage collaborators, core labs, or commercial CROs to execute any fraction of the project.
- Past recipients of HDI Scholar-Innovator awards may submit new and distinct proposals but may not seek additional support for previously funded projects.
The goal of the Harrington Scholar-Innovator Grant Program is to advance physician-scientist-initiated projects aimed at clinical introduction of new medicines (drugs or biologics). The specific focus of eligible projects includes fundamental discovery (elucidation of novel targets), novel drugs and biologics or drug-device combinations.
Grant Amounts and Number
Harrington Discovery Institute will provide up to 10 new grants each year. Awards will include up to $200,000 in financial support over 2 years. Investigators will also receive drug discovery support and related resources through the Innovation Support Center (ISC), including consulting services from highly experienced, drug- development personnel, clinical development oversight, business and commercialization assistance, help identifying and securing additional financial support, and related services. The Harrington Discovery Institute and ISC staff will work closely with the awardee and the awardee’s institution to maximize the clinical and commercial potential of selected projects.
Submission and Selection Process
The 2014 Harrington Scholar-Innovators will be selected by a two-stage process. Interested applicants are asked to submit a Letter of Intent by 5:00 PM EDT May 15, 2013. Invitations to submit a full proposal will be sent to applicants via email mid-late June 2013, and proposals will be due on August 2, 2013.
The review panel will consist of subject matter experts with scientific expertise in the area(s) designated in the application and seasoned professionals with expertise in drug discovery and commercialization. The review panel will score each application on a number of criteria, including but not limited to:
- quality of science
- medical need and
- clinical impact
Harrington Discovery Institute’s Scientific Advisory Board will make the final selections of grant winners. Applicants who fail to fill out their applications by the deadline and/or in accordance with the detailed application instructions are subject to disqualification at the outset of the review period or any time during the review period.
Letters of Intent will be reviewed and the Harrington Discovery Institute will select projects believed to have the greatest clinical potential and demonstrating a highly innovative approach to significant clinical problems. The Harrington Discovery Institute will subsequently invite selected PIs to submit a full proposal. Notices will be sent in mid-late June 2013 and full proposals will be due on August 2, 2013. Barring any unforeseen delays, final selection of winners will be in November and the effective date of this grant will be January 1, 2014.
Harrington Discovery Institute is not able to provide reviewers’ comments on Letters of Intent or applications.
Members of Harrington Discovery Institute’s review panel and Scientific Advisory Board will complete mutual Confidentiality & Disclosure Agreements with Harrington Discovery Institute. Non public applicant information will, therefore, be kept confidential (and limited in distribution to the reviewers and Harrington Discovery Institute administrative team). The abstract summary, including the applicant’s name and institutional affiliation, for those selected as Scholar-Innovators, may be used by Harrington Discovery Institute for publicity and marketing purposes (on the Harrington Discovery Institute website, news releases, etc.) at Harrington Discovery Institute's sole discretion. Applicants acknowledge that University Hospitals Health System may conduct research that is related to or competitive with proposals submitted by applicants, but University Hospitals Health System commits not to use information submitted by applications in connection with such research.
Harrington Discovery Institute will take questions about the application process or the grant program via email from applicants at email@example.com.
Sponsoring Institution Requirements
Investigators may apply from accredited academic medical centers, research institutions, or universities in the U.S. and U.S. territories. Institutions must provide the necessary facilities and infrastructure for the research, and accept the conditions of the Grant, including the Budget & Use of Funds. They must assure compliance with the prevailing national guidelines for animal and human studies and provide proper oversight of the Grant funds.
Sponsoring institutions must safeguard the rights and welfare of individuals who participate as subjects in research activities by reviewing proposed activities through an Institutional Review Board (IRB) as specified by the U.S. Department of Health and Human Services Office for Human Research Protections, HHS OHRP. Additionally, the Grantee’s institution must assure appropriate governance of animal studies. IRB approval and IACUC numbers are not required at the time of application, but must be provided for final signature of the Grant Agreement, which will be sent to Grantees shortly after they have been selected.
Additionally, sponsoring institutions must adhere to current U.S. Department of Health and Human Services guidelines regarding financial conflict of interest, recombinant DNA, and research misconduct.
Annual Scientific Symposium
Part of Harrington Discovery Institute’s mission is to build a broad connected community of physician-scientist-innovators. Harrington Discovery Institute will hold an annual symposium that current Grantees are required to attend. The Symposium, held in late spring at University Hospitals Case Medical Center in Cleveland, OH, will bring together Harrington Scholar-Innovators, members of the Innovation Support Center, drug development experts, members of the Scientific Advisory Board and other national physician-scientist leadership. Grantees are expected to present their project and findings-to-date. A stipend for travel and lodging will be provided by Harrington Discovery Institute, subject to the terms of the Grant Agreement.
Use of Funds
General: No more than $10,000 of the total grant can be used for capital expenditures or equipment. The award may only be used for direct project expenses, not for institutional overhead.
Salary: The award may not be applied to the PI’s salary. The award may be used to cover salaries for post-docs equivalent to the % effort devoted to the project.
Travel: The award may not be used for travel, meetings, professional fees, publication fees, etc.
Harrington Discovery Institute does not claim any rights whatsoever to patents copyrights or trademarks to other intellectual property created as a result of work sponsored by Scholar-Innovator Grants (“Intellectual Property”). On all aspects of Intellectual Property, Principal Investigators are encouraged to confer with their technology transfer office and/or office of sponsored programs for guidance. Harrington Scholar-Innovators may seek input and advice on patent protection, including ways to strengthen intellectual property, from the Innovation Support Center, which also claims no rights whatsoever to IP.
Grantees should take measures to ensure protection of any Intellectual Property in accord with Federal and institutional requirements.
NIH Data Sharing Policy
Scientific research depends on the free flow of information and ideas. A data-sharing plan is not requested or required. However, in its annual evaluation of progress as outlined in the Scientific Reporting & Review of Progress section below, Harrington Discovery Institute will consider, as part of the criteria for continued funding, adequate progress in sharing unique research resources developed with funds from the Grant, as well as a demonstrated willingness to make research resources developed during the project widely available to the research community.
In accordance with a mission to advance research and accelerate the development of new therapeutics, the HDI encourages compliance with the National Institutes of Health (NIH) data sharing policy. Unique research resources (developed with funds from the Grant should be made available to the research community according to NIH guidelines. Grantees may distribute reagents and data without HDI approval in compliance with the norms and rules of their institution.
Scientific Reporting & Review of Progress
Yearly renewal of the Grant is dependent on timely submission of a written progress report, as well as attendance at the annual Scientific Symposium. The progress report should be approximately one and not exceed two pages and should cover findings to-date, status, and future direction. It should also include a one page financial report accounting for expenditures during the prior period and an updated budget (if applicable). The report is due on November 15th each year.
Changes to Project
A significant change in the project scope or work should be discussed with Harrington Discovery Institute’s Director and approved in writing or by email by the Director.
Grants may be transferred to another institution that agrees to assume the Policies, Terms & Conditions of the Grant. Permission to transfer a Grant to another institution must be obtained from Harrington Discovery Institute’s Director.
Timeline & Grant Agreement
Winners and those rejected will be informed in November. Winners of the grant must be prepared to sign the Grant Agreement by mid-December. The Grant start date is January 1 and runs on a calendar year basis.
Grants are funded by Harrington Discovery Institute, after the recommendations of the Scientific Advisory Board. Harrington Discovery Institute Staff will assure compliance with Grant policies and will be responsible for all administrative matters.
The Principal Investigator and his or her institution are solely responsible for execution of the project, including compliance with all relevant Federal and State laws and guidelines.
Harrington Discovery Institute reserves the right to refine and amend policies as required.